MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines

被引:66
|
作者
Hummel, Richard [1 ,2 ]
Sie, Corina [1 ]
Watson, David I. [1 ]
Wang, Tingting [1 ]
Ansar, Alfiya [1 ]
Michael, Michael Z. [3 ]
Van der Hoek, Mark [4 ]
Haier, Joerg [5 ]
Hussey, Damian J. [1 ]
机构
[1] Flinders Univ S Australia, Med Ctr, Dept Surg, Bedford Pk, SA 5042, Australia
[2] Univ Munster, Dept Gen & Visceral Surg, D-48149 Munster, Germany
[3] Flinders Univ S Australia, Dept Gastroenterol & Hepatol, Bedford Pk, SA 5042, Australia
[4] Adelaide Microarray Ctr, SA Pathol, Adelaide, SA 5000, Australia
[5] Univ Munster, Ctr Comprehens Canc, D-48149 Munster, Germany
基金
英国医学研究理事会;
关键词
Esophageal cancer; MicroRNA; Chemotherapy; Resistance; Target; MULTIDRUG-RESISTANCE; CONFERS RESISTANCE; CARCINOMA; CHEMORADIOTHERAPY; METAANALYSIS; SURVIVAL; RECEPTOR;
D O I
10.3748/wjg.v20.i40.14904
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To investigate expression of microRNA (miRNA) and potential targets in chemotherapy resistant esophageal cancer cell lines. METHODS: An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. RESULTS: Chemotherapy resistant sublines were found to have specific miRNA signatures, and these miRNA signatures were different for the cisplatin vs 5-FU resistant cells from the same tumor cell line, and also for EAC vs ESCC cells with resistance to the same specific chemotherapy agent. Amongst others, miR-27b-3p, miR-193b-3p, miR-192-5p, miR-378 a-3p, miR-125a-5p and miR-18a-3p were dysregulated, consistent with negative posttranscriptional control of KRAS, TYMS, ABCC3, CBL-B and ERBB2 expression via these miRNAs. CONCLUSION: The current study supports the hypothesis that microRNA expression has an impact on chemotherapy resistance in esophageal cancer. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:14904 / 14912
页数:9
相关论文
共 50 条
  • [31] Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis
    Wang, He
    Li, Sihan
    Liu, Tingting
    Chen, Jun
    Dang, Jun
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [32] Investigation of Radiosensitivity Gene Signatures in Cancer Cell Lines
    Hall, John S.
    Iype, Rohan
    Senra, Joana
    Taylor, Janet
    Armenoult, Lucile
    Oguejiofor, Kenneth
    Li, Yaoyong
    Stratford, Ian
    Stern, Peter L.
    O'Connor, Mark J.
    Miller, Crispin J.
    West, Catharine M. L.
    PLOS ONE, 2014, 9 (01):
  • [33] MicroRNA expression signatures of stage, grade, and progression in clear cell RCC
    Gowrishankar, Banumathy
    Ibragimova, Ilsiya
    Zhou, Yan
    Slifker, Michael J.
    Devarajan, Karthik
    Al-Saleem, Tahseen
    Uzzo, Robert G.
    Cairns, Paul
    CANCER BIOLOGY & THERAPY, 2014, 15 (03) : 329 - 341
  • [34] Identification of novel microRNA targets based on microRNA signatures in bladder cancer
    Ichimi, Takahiro
    Enokida, Hideki
    Okuno, Yasushi
    Kunimoto, Ryo
    Chiyomaru, Takeshi
    Kawamoto, Ken
    Kawahara, Kazuya
    Toki, Kazuki
    Kawakami, Kazumori
    Nishiyama, Kenryu
    Tsujimoto, Gozoh
    Nakagawa, Masayuki
    Seki, Naohiko
    INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (02) : 345 - 352
  • [35] MicroRNA-29b regulates osteopontin dependent proliferation function and cell cycle in esophageal cancer lines
    Chen, Bolin
    Du, Juan
    Yang, Min
    Li, Linqing
    Liu, Liyu
    Li, Kang
    Luo, Zhenqin
    Wu, Lin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (10): : 14341 - 14349
  • [36] Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer
    Midthun, Lauren
    Kim, Sungjin
    Hendifar, Andrew
    Osipov, Arsen
    Klempner, Samuel J.
    Chao, Joseph
    Cho, May
    Guan, Michelle
    Placencio-Hickok, Veronica R.
    Gangi, Alexandra
    Burch, Miguel
    Lin, De-Chen
    Waters, Kevin
    Atkins, Katelyn
    Kamrava, Mitchell
    Gong, Jun
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 14 (02) : 511 - 524
  • [37] Radiation Modulation of MicroRNA in Prostate Cancer Cell Lines
    Josson, Sajni
    Sung, Shian-Ying
    Lao, Kaiqin
    Chung, Leland W. K.
    Johnstone, Peter A. S.
    PROSTATE, 2008, 68 (15) : 1599 - 1606
  • [38] Neoadjuvant chemotherapy versus chemoradiation for esophageal cancer: no survival difference does not mean no differences
    Pimiento, Jose Mario
    Hofffe, Sarah E.
    Almhanna, Khaldoun
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S1281 - S1283
  • [39] Survival and complications after neoadjuvant chemotherapy or chemoradiotherapy for esophageal cancer: a meta-analysis
    Han, Jinmin
    Wang, Zhongtang
    Liu, Chengxin
    FUTURE ONCOLOGY, 2021, 17 (17) : 2257 - 2274
  • [40] Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases
    Chen, Yongshun
    Cheng, Xinyu
    Song, Haixia
    Wu, Abraham J.
    Ku, Geoffrey Y.
    Lee, Percy
    Slingerland, Marije
    Koyanagi, Kazuo
    Ke, Shaobo
    Qiu, Hu
    Shi, Wei
    Gao, Yi
    Chen, Jiamei
    JOURNAL OF THORACIC DISEASE, 2019, 11 (04) : 1536 - 1545